These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 29368539)
1. Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Cohen JA; Hunter SF; Brown TR; Gudesblatt M; Thrower BW; Llorens L; Souza-Prien CJ; Ruby AE; Chernoff DN; Patni R Mult Scler; 2019 Apr; 25(4):601-609. PubMed ID: 29368539 [TBL] [Abstract][Full Text] [Related]
2. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Cohen JA; Cameron MH; Goldman MD; Goodman AD; Miller AE; Rollins A; Llorens L; Patni R; Elfont R; Johnson R Mult Scler; 2022 Apr; 28(5):817-830. PubMed ID: 34449295 [TBL] [Abstract][Full Text] [Related]
3. Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. Pahwa R; Isaacson S; Jimenez-Shaheed J; Malaty IA; Deik A; Johnson R; Patni R Parkinsonism Relat Disord; 2019 Mar; 60():118-125. PubMed ID: 30292734 [TBL] [Abstract][Full Text] [Related]
11. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077 [TBL] [Abstract][Full Text] [Related]
12. Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease. Elmer LW; Juncos JL; Singer C; Truong DD; Criswell SR; Parashos S; Felt L; Johnson R; Patni R CNS Drugs; 2018 Apr; 32(4):387-398. PubMed ID: 29532440 [TBL] [Abstract][Full Text] [Related]
13. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Coleman CI; Sobieraj DM; Marinucci LN Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939 [TBL] [Abstract][Full Text] [Related]
14. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern. Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672 [TBL] [Abstract][Full Text] [Related]
15. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. Hauser RA; Pahwa R; Tanner CM; Oertel W; Isaacson SH; Johnson R; Felt L; Stempien MJ J Parkinsons Dis; 2017; 7(3):511-522. PubMed ID: 28777755 [TBL] [Abstract][Full Text] [Related]
16. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050 [TBL] [Abstract][Full Text] [Related]